2025年4月4日 星期五
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2022, Vol. 28 Issue (11): 1805-1808    DOI: 10.3969/j.issn.1006-6233.2022.11.09
  论著 本期目录 | 过刊浏览 | 高级检索 |
非小细胞肺癌程序性死亡配体1与EGFR基因突变相关性研究
鄢丽敏, 李雪梅, 雷冲, 闫继东, 张志勇
河北省唐山市工人医院, 河北 唐山 063000
Correlation Studies of Programmed Death Ligand 1 and EGFR Gene Mutations in Non-Small Cell Lung Carcinoma
YAN Limin, LI Xuemei, LEI Chong, et al
Hebei Tangshan Gongren Hospital, Hebei Tangshan 063000, China
全文: PDF (1908 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的: 通过分析程序性死亡配体1(Programmed cell death-ligand 1,PD-L1)表达与表皮生长因子受体(Epidermal growth factor receptor,EGFR)基因突变状态之间的相关性,找到EGFR突变型非小细胞肺癌(Non small cell lung carcinoma NSCLC)免疫治疗效果差的原因,为EGFR突变型NSCLC患者的精准诊疗提供参考依据。方法: 收集唐山市工人医院病理科2020年至2021年间同时行EGFR基因检测及PD-L1免疫组化染色的NSCLC病例共308例,分析PD-L1表达强度与EGFR基因突变率的关系,EGFR突变情况与PD-L1表达强度的相关性。结果: PD-L1阴性、弱阳性、中等阳性和强阳性的病例EGFR突变率分别为71.30%、57.55%、50.00%、44.12%(P=0.017,r=-0.176);PD-L1低表达率和高表达率在EGFR突变型中分别为74.19%和25.81%,在野生型中分别为62.30%和37.70%(P=0.027)。结论: PD-L1表达强度与EGFR突变率之间呈现负相关,PD-L1表达越强,EGFR的突变率越低;EGFR突变型NSCLC患者中PD-L1更倾向于低表达。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 非小细胞肺癌表皮生长因子受体程序性死亡配体1    
AbstractObjective: To find out the reason for poor immunotherapy effect of epidermal growth factor receptor (EGFR) mutant non small cell lung carcinoma (NSCLC) by analyzing the correlation between programmed cell death-ligand 1 (PD-L1) expression and EGFR gene mutation status, and to provide reference for precise diagnosis and treatment of EGFR-mutant NSCLC patients.Methods: A total of 308 NSCLC patients who underwent EGFR gene detection and PD-L1 immunohistochemical staining at the same time in the Department of Pathology of Tangshan Gongren Hospital from 2020 to 2021 were collected. The relationship between PD-L1 expression intensity and EGFR gene mutation rate, and the correlation between EGFR mutation status and PD-L1 expression intensity, were analyzed. Results: EGFR mutation rates were 71.30%, 57.55%, 50.00% and 44.12% (P=0.017, r=-0.176) in PD-L1 negative, weakly positive, moderately positive and strongly positive patients, respectively. The low and high expression rates of PD-L1 were 74.19% and 25.81% in the EGFR mutant NSCLC, and 62.30% and 37.70% in the wild type (P=0.027). Conclusion: There is a negative correlation between the expression intensity of PD-L1 and EGFR mutation rate. The higher the expression of PD-L1, the lower the mutation rate of EGFR. Patients with EGFR mutant NSCLC were more likely to have low expression of PD-L1.
Key wordsNon small cell lung cancer    Epidermal growth factor receptor    Programmed cell death-ligand 1
    
基金资助:河北省省级科技计划自筹经费项目,(编号162777167);河北省医学科学研究重点课题计划项目,(编号20171381)
通讯作者: 张志勇   
引用本文:   
鄢丽敏, 李雪梅, 雷冲, 闫继东, 张志勇. 非小细胞肺癌程序性死亡配体1与EGFR基因突变相关性研究[J]. 河北医学, 2022, 28(11): 1805-1808.
YAN Limin, LI Xuemei, LEI Chong, et al. Correlation Studies of Programmed Death Ligand 1 and EGFR Gene Mutations in Non-Small Cell Lung Carcinoma. HeBei Med, 2022, 28(11): 1805-1808.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2022.11.09     或     http://www.hbyxzzs.cn/CN/Y2022/V28/I11/1805
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发